###-----SETUP----###
simulations: 5000
progress: True

###-----TREATMENT ALLOCATION----###
# Assuming 77 year old male - https://www.cancerdata.nhs.uk/treatments
treatment-distributions: [0.335175413, 0.083228036, 0.209740598, 0.147376245, 0.049030028, 0.074862494, 0.072866805, 0.027720381]

###-----IMPLEMENTATION----###
tablet-based-assessments: False
face-to-face-assessments-nurse: True
face-to-face-assessments-consultant: True
face-to-face-assessments-registrar: False
telephone-assessments: False
ga-changing-management-at-mdt-level: True
only-undergoing-chemotherapy: False
only-undergoing-surgery: False

###-----GA EFFECTS--------###
reduced-los-effect: 1 # https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12012
reduced-chemotherapy-toxicity-effect: True # https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12010
reduced-er-visits-effect: 1 # https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12011 
reduced-itu-admissions-effect: 1
reduced-post-surgical-readmissions-effect: 1 # https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12012
reduced-surgical-complications-effect: True

###-----SURGERY----------###
# https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868204/ 
# https://academic.oup.com/ejcts/article/54/3/560/4921284 
# https://publishing.rcseng.ac.uk/doi/pdf/10.1308/003588413X13629960046039 
# https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-9-202
# https://bci.leeds.ac.uk/wp-content/uploads/sites/24/2019/04/Length-of-Stay.pdf 
bed-days-alpha: 2.14
bed-days-beta: 3.04

requiring-itu: 0.097 #https://pubmed.ncbi.nlm.nih.gov/21732168/,https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.12012

# https://core.ac.uk/download/pdf/82145253.pdf
# https://pubmed.ncbi.nlm.nih.gov/25988303/
# https://pubmed.ncbi.nlm.nih.gov/28688676/
# https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417637/
# https://journals.sagepub.com/doi/full/10.1177/1745506520965899
# https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.31987
readmissions-alpha: 3.6 
readmissions-beta: 31.5

###-----GENERAL---------###
# ER Visits - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5001935/
er-visits-alpha: 0.78 
er-visits-beta: 6.31

###-----OUTCOMES--------###
initial-qaly-alpha: 37.79 # mean = 0.73, sd = 0.0611 #(mean of all cancer states 0.692 + 0.673 + 0.560 + 0.765 + 0.756 + 0.758 + 0.687 + 0.822 + 0.677) https://journals.sagepub.com/doi/abs/10.1177/0272989X11401031#abstract, https://academic.oup.com/ageing/advance-article/doi/10.1093/ageing/afab094/6296883 and AgeFiT (? need population norms for age and sex)
initial-qaly-beta: 13.93 #0.0757 #SD from Excel

10-year-survival-probabilities: [[ 0.967711, 0.612698, 0.52797, 0.473091, 0.438158, 0.413269, 0.3908, 0.370723, 0.354533, 0.343723, 0.339788 ], [ 0.967711, 0.571380518, 0.464723943, 0.395256173, 0.356781234, 0.328020278, 0.301236405, 0.277092946, 0.259023145, 0.243354875, 0.230547149 ]]

nice-recommended-yearly-discount: 0.035 # Discount by 3.5%/year NICE. Developing NICE Guidelines: The Manual. London: National Institute for Health and Care Excellence,2014.

chemotherapy-qaly-decrement-alpha: 77.05 #mean 0.32Â±SD0.03 https://www.sciencedirect.com/science/article/pii/S0959804911004230#s0120
chemotherapy-qaly-decrement-beta: 163.73
